Преображенский Д. В., Сидоренко Б. А., Патарая С. А., Скорик А. В. Плейотропные эффекты ингибиторов ангиотензин-превращающего фермента: существуют ли особые преимущества у сульфгидрильных препаратов?. Кардиоваскулярная терапия и профилактика. 2008;7(1):116-123.
1. Opie LH. Angiotensin converting enzyme inhibitors. 3th edition. New York 1999.
2. Сидоренко Б.А., Преображенский Д.В. Ингибиторы ангиотензин-превращающего фермента. Москва 1998.
3. Сидоренко Б.А., Преображенский Д В., Батыралиев Т А. Ингибиторы ангиотензин-превращающего фермента. 26е издание. Москва 2007.
4. Преображенский Д.В., Сидоренко Б.А., Скавронская Т.В. и др. Зофеноприл – кардиопротективный ингибитор ангиотензин-превращающего фермента: клиническая фармакология и опыт применения при лечении артериальной гипертензии. РКЖ 2006; 1: 87–94.
5. Cushman DW, Wang FL, Fung WC, et al. Comparisons in vitro, ex vivo, and in vivo of the the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 1989; 28 (Suppl. 2): 115S-31.
6. Cushman DW, Wang FL, Fung WC, et al. Differentiation of angiotensin converting enzyme (ACE) inhibitors by selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989; 2(4): 294–306.
7. Subissi A, Evangelista E, Giachetti A. Preclinical profile of zofenopril: An angiotensin converting enzyme inhibitor with pecular cardioprotective properties. Cardiovascular Drug Reviews 1999; 17: 115–33.
8. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148: e5 (K1–7).
9. Grover GI, Sleph PG, Dzwonczyk S, et al. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection. J Cardiovasc Pharmacol 1991; 18(4): 478–86.
10. Liu X, Engelman RM, Rousou JA, et al. Attenuation of myocardial reperfusion injury by sulhydryl-contained angiotensin converting enzyme inhibitors. Cardiovasc Drug Ther 1992; 6: 437–43.
11. Ferrari R, Cargnoni A, Curello S, et al Protection of the ischemic myocardium by the converting6enzyme inhibitor zofenopril: insight into its mechanism of action. J Cardiovasc Pharmacol 1992; 20: 694–704.
12. Porzyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am Heart J 1991; 121(5): 1315–30.
13. Anning PB, Crocott-Mason RM, Lewis MJ. Effects of sulhydryl- and non-sulhydryl-contained ACE-inhibitors on left ventricular relaxation in isolated guinea heart. Endothelium 1997; 5(4): 265–75.
14. Borghi C, Ambrosioni E. The role of zofenopril in the treatment of cardiovascular diseases. Milano 2001.
15. Borghi C, Bacchelli S, Esposti DD, Ambrosioni E. A review of the angiotensin converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother 2004; 5(9): 1965–77.
16. van Gilst WH, de Graeff PA, de Leeue MJ, et al. Converting enzyme inhibitors and the role of sulhydryl group in the potentiation of exo- and endogeneous nitrovasodilators. J Cardiovasc Pharmacol 1991; 18: 429–36.
17. Ambrosioni E, Borghi C, Magnani B, et al. for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) study investigators. The effect of the angiotension-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80–5.
18. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensinconverting enzyme inhibition on endothelial function function and oxidant stress. Eur J Pharmacol 2003; 482(1–3): 95–9.
19. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33(1): 42–54.
20. de Negris F, D’Armiento FP, Casini A, et al. Chronic treatment with sulhydryl angiotensin converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001; 81: 107–15.
21. Evangelista E. Антиатеросклеротическое действие ингибиторов ангиотензин-превращающего фермента. Cons Med 2007; 5: 24–6.
